Form 4: Acasti Pharma Inc. Executive Granted Stock Options
SEC Form 4 Filing
Carrie D'Andrea, VP of Program Management at Acasti Pharma Inc., was granted stock options on May 6, 2024.
Summary
- Carrie D'Andrea, VP of Program Management at Acasti Pharma Inc., filed a Form 4 with the SEC.
- The filing reports the grant of stock options on May 6, 2024.
- D'Andrea was granted 19,740 stock options with an exercise price of $2.96.
- The options vest quarterly in equal installments over a 36-month period and expire on May 6, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant may incentivize the VP of Program Management to improve company performance, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of earliest transaction (grant of stock options) |
| 05/06/2024 | Stock options granted under the Acasti Pharma Stock Option Plan |
| 05/06/2034 | Expiration date of the stock options |
| 05/08/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.